Publications

Please contact us for further information about any of the key publications:

BARD1

1. Ratajska M, Matusiak M, Kuzniacka A, Wasag B, Brozek I, Biernat W, Koczkowska M, Debniak J, Sniadecki M, Kozlowski P, Klonowska K, Pilyugin M, Wydra D, Laurent G, Limon J, Irminger-Finger Cancer predisposing BARD1 mutations affect exon skipping and are associated with overexpression of specific BARD1 isoforms. Oncol Rep. 2015 Nov;34(5):2609-17.
2. André PA, Prêle CM, Vierkotten S, Carnesecchi S, Donati Y, Chambers RC, Pache JC, Crestani B, Barazzone-Argiroffo C, Königshoff M, Laurent GJ, Irminger-Finger BARD1 mediates TGF-β signaling in pulmonary fibrosis. Respir Res. 2015 Sep 29;16:118.
3. Irminger-Finger I, Ratajska M, Pilyugin M. New concepts on BARD1: Regulator of BRCA pathways and beyond. Int J Biochem Cell Biol. 2016 Mar; 72:1-17.
4. Marzec KA, Martino-Echarri E, Irminger-Finger I, Henderson BR. BARD1 splice variants display mislocalization in breast cancer cells and can alter the apoptotic response to cisplatin. Cancer Lett. 2016 Jul 28;381(1):149-155.

hTERT

1. Allison DB, Sharma R, Cowan ML, VandenBussche CJ: Evaluation of Sienna Cancer Diagnostics hTERT antibody on 500 consecutive urinary tract specimens. Acta Cytologica 2018, DOI: 10.1159/000489181.
2. Lalla M, VandenBussche CJ, Huan G, Anderson P: The hTERT ICC Test as an Adjunct to Urine Cytology: A Longitudinal Follow-Up. Poster presented at ICC 2020: 22nd International Conference on Cytology London, United Kingdom during May 21-22, 2020.

NETs

1. Carlos Salomon, Saumya Das, Uta Erdbrügger, Raghu Kalluri, Sai Kiang Lim, Jerrold M Olefsky, Gregory E Rice, Susmita Sahoo, W Andy Tao, Pieter Vader, Qun Wang, Alissa M Weaver: Extracellular Vesicles and Their Emerging Roles as Cellular Messengers in Endocrinology: An Endocrine Society Scientific Statement. Endocrine Reviews, June 2022.
   
2. Poster Presentation: Differential detection of cancer-derived extracellular vesicles using combined antibody functionalized magnetic beads and infrared spectroscopy,  Thomas STEWART, Tamkin AHMADZADA, Sophia AMERENA-COWIE, Emily STEIN, Peter FRENCH, Gregory RICE, Michelle WOOD, Joonsup LEE, Elham HOSSEINI-BEHESHTI, Peter A. LAY, Georges E. GRAU

SubB2M

1. Day CJ, Paton AW, Higgins MA, Shewell LK, Jen FE-C, Schulz BL, Herdman BP, Paton JC, Jennings MP (2017). Structure aided design of a Neu5Gc specific lectin. Nature Scientific Reports; 7: 1495
2. Wang J, Shewell LK, Paton AW, Paton JC, Day CJ, Jennings MP (2018). Specificity and utility of SubB2M, a new N-glycolylneuraminic acid lectin. Biochemical and Biophysical Research Communications 500: 765-771
3. Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP (2018). Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M. Biochemical and Biophysical Research Communications 507: 173-177. https://doi.org/10.1016/j.bbrc.2018.11.001
4. Shewell LK, Day CJ, Kutasovic JR, Abrrahams JL, Wang J, Poole J, Niland C, Ferguson K, Saunus JM, Lakhani SR, von Itzstein M, Paton JC, Paton AW, Jennings MP. N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease. bioRxiv (preprint Aug 2021). doi: https://www.biorxiv.org/content/10.1101/2021.06.21.449179v2